Abstract
The locus coeruleus (LC) is involved in several neural pathways responsible for some somatic and emotional processes, such as pain and depression; its activity is regulated by several receptors, such as opioid, α2-adrenergic, and 5-hydroxytryptamine (5-HT)1A receptors. The present study investigates the in vivo effects of venlafaxine, an antidepressant with analgesic properties, on locus coeruleus neurons, and its modulation by opioid, α2-adrenergic, and 5-HT1A receptors. The results show that acute administration of venlafaxine produced a dose-dependent, complete inhibition of LC activity. This inhibitory effect was not reversed by the opioid receptor antagonist naloxone, but subsequent administration of idazoxan, an α2-adrenoceptor antagonist, did reverse it. The preadministration of the 5-HT1A receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 μg/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED50 by 56 and 44%, respectively. A 14-day treatment with venlafaxine (40 mg/kg/day) induced a suppression of the firing activity of LC neurons. In these treated animals, venlafaxine produced an inhibitory effect similar to that in nontreated animals. This inhibitory effect was not reversed by naloxone, but it was reversed by idazoxan. In addition, the preadministration of 8-OH-DPAT (40 μg/kg) significantly enhanced the venlafaxine effect, decreasing the ED50 by 60%. These results suggest that the effect of venlafaxine on LC neurons is modulated by α2-adrenergic and 5-HT1A receptors, and not by opioid receptors. These data could contribute to the further understanding of the antidepressant and analgesic mechanism of action of venlafaxine.
Footnotes
-
This study has been supported by “Fondo de Investigación Sanitaria” (PI031430) and “Plan Andaluz de Investigación” (CTS-510).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.107.120915.
-
ABBREVIATIONS: 5-HT, 5-hydroxytryptamine (serotonin); NA, noradrenaline; SNRI, 5-hydroxytryptamine (serotonin)/noradrenaline reuptake inhibitor; LC, locus coeruleus; 8-OH-DPAT (DPAT), 8-hydroxy-2-dipropylaminotetralin; ANOVA, analysis of variance; NLX, naloxone; VLX, venlafaxine.
- Received February 2, 2007.
- Accepted April 11, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|